期刊文献+

Ⅱ期结肠癌患者的预后分析 被引量:3

Analysis of prognostic factors in patients with stage Ⅱ colon cancer
下载PDF
导出
摘要 目的探讨Ⅱ期结肠癌根治术后的预后影响因素,评价术后辅助化疗在Ⅱ期结肠癌中的价值。方法回顾性分析127例接受根治性手术切除的Ⅱ期结肠癌患者的临床资料并进行随访,采用Kaplan-Meier法进行生存分析,采用Log-rank法进行生存比较,COX比例风险模型进行多因素分析。结果单因素分析显示,年龄、大体分型、组织学类型、侵犯邻近器官、脉管浸润、淋巴结解剖个数及术前CEA为不良预后因素(P<0.05);进一步多因素分析显示,组织学类型和脉管浸润是影响生存的独立预后因素。全组共85.0%(108/127)的患者接受了术后辅助化疗,辅助化疗组和未化疗组的5年生存率差异无统计学意义(P>0.05),但辅助化疗组中具有不良预后因素的患者显著多于未化疗组(P=0.000)。结论Ⅱ期结肠癌的预后与多种因素有关,组织学类型和脉管浸润是影响生存的独立预后因素。建议对存在不良预后影响因素的Ⅱ期结肠癌患者给予辅助化疗。 Objective To explore the prognostic factors and to evaluate the value of adjuvant chemotherapy in the patients with stage Ⅱ colon cancer.Methods From January 2000 to December 2005,127 patients with stage Ⅱ colon cancer who had received radical surgery were retrospectively analyzed and followed up,the survival rates were estimated by Kaplan-Meier method and compared with Log-rank method.COX proportional hazards model was used for multivariate analysis.Results Univariate analysis showed that the age,gross type,histological type,violation of nearby organs,vascular invasion,lymph nodes dissection and preoperative CEA were factors of adverse prognostic(P0.05);further multivariate analysis showed that histological type and vascular invasion were independent prognostic factors affecting survival.The total of 85.0%(108/127) of patients received adjuvant chemotherapy,5-year survival rate of adjuvant chemotherapy group and no chemotherapy group was not significantly related(P0.05),but the number of the patients with adverse prognostic factors in adjuvant chemotherapy group was significantly more than no chemotherapy group(P=0.000).Conclusion The prognosis of stage Ⅱ colon cancer is affected by a variety of factors,histological type and vascular invasion are independent prognostic factors affecting survival.The patients of stage Ⅱ colon cancer with poor prognosis need adjuvant chemotherapy.
作者 许春蕾 唐勇
出处 《实用肿瘤杂志》 CAS 2012年第3期259-263,共5页 Journal of Practical Oncology
关键词 结肠肿瘤 化学疗法 辅助 因素分析 统计学 预后 回顾性研究 colonic neoplasms chemotherapy adjuvant factor analysis statistical prognosis retrospective studies
  • 相关文献

参考文献11

  • 1O, Connell J, Maggard M, Ko C. Colon cancer survival rates with the new American Joint Committee On Cancer Sixth Edition Staging [ J ]. J Natl Cancer Inst, 2004,96 (19) :1420.
  • 2Morris M, Platell C, McCaul K. Survival rates for stage Ⅱ colon cancer patients treated with or without chemotherapy in a population-based setting [ J ]. Int J Colorectal Dis, 2007,22 ( 8 ) :887 - 895.
  • 3Takayama T, Kochi M. Clinical identification of colorectal cancer patients benefiting from adjuvant uracil-tegafur (UFT) :a randomized controlled trial[J]. J Cancer Res Clin Oncol,2008,134(12) : 1319 - 1323.
  • 4Bennouna J, Saunders M, Douillard JY. The role of UFT in metastatic colorectal cancer[ J ]. Ontology, 2009,76 (5) :301 -310.
  • 5Twelces C, Wong A, Nowacki M,et al. Capecitabine as adjuvant therapy for stage Ⅲ colon cancer [J]. N Engl Med, 2005,352 (26) : 2696 - 2704.
  • 6Glodberg RM, Morton RF, Sargent DJ, et al. A randomized controlled trial of fluorouracil plus Leucovorin, irinoteean, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer[J]. J Clin Oncol,2004,22( 1 ) :23 - 30.
  • 7卢震海,万德森,王国强,方淯靖,周志伟,潘志忠,陈功,李力人,伍小军,丁培荣.1126例结肠癌患者的临床病理特征及预后分析[J].广东医学,2007,28(6):908-910. 被引量:13
  • 8万德森,丁培荣,伍小军,李力人,潘志忠,周志伟,卢震海,陈功.直肠癌根治术的远期疗效分析[J].中华胃肠外科杂志,2005,8(4):301-303. 被引量:18
  • 9Lacy AM, Garcia-Valdecasas JC, Delgado S, et al. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomized trial [ J ]. Lancet, 2002,359 ( 9325 ) : 2224 - 2229.
  • 10Jayne DG, Guillou, Thorpe H, et al. Randomized trial of laparoscopic -assisted resection of colorectal carcinoma : 3-year results of the UK MRC CLASICC trial group [ J ]. J Clin Oncol,2007,25 (21 ) : 3061 - 3068.

二级参考文献19

  • 1王晓娜,梁寒,王家仓,王宝贵.1829例结直肠癌患者的临床病理特征及预后分析[J].中华胃肠外科杂志,2004,7(6):439-442. 被引量:36
  • 2梁寒,郝希山,王仆,王晓娜,李景武,王家仓,王殿昌.影响直肠癌患者术后生存的多因素Cox回归分析[J].中华肿瘤杂志,2004,26(11):688-691. 被引量:18
  • 3任镜清,周志伟,万德森,卢震海,陈功,王国强,唐绍贤,王俊江.结肠癌根治术后复发转移的单因素和多因素分析[J].癌症,2006,25(5):591-595. 被引量:33
  • 4伍小军 万德森 见:万德森 潘志忠主编.大肠癌的预后因素[A].见:万德森,潘志忠主编.大肠癌:第 1版[C].北京:中国医药科技出版社,2004.359-360.
  • 5Hermanek P.Staging systems-A review.In:Soreide O,Norstein J,eds.Rectal cancer surgery.Berlin:Springer,1997.49-61.
  • 6Weber TK,Kent TS,Bennett AM.Combined modality treatment for rectal cancer.Princ Pract Oncol,2003,17:1-15.
  • 7Fabio FD,Nascimbeni R,Villanacci V,et al.Prognostic variables for cancer-related survival in node-negative colorectal carcinoma.Dig Surg,2004,21:128-133.
  • 8Raab R,Meyer HJ,Werner U.Surgery for rectal cancer.In:Soreide O,Norstein J.eds.Rectal cancer surgery.Berlin:Springer,1997.173-184.
  • 9WEYANT M J,CAROTHERS A M,MAHMOUD N N,et al.Reciprocal expression of E Ralpha and E Rbeta is associated with estrogen-mediated modulation of intestinal tumorigenesis[J].Cancer Res,2001,61:2 547 -2 551.
  • 10CHIANG J M,CHEN M C,CHANGCHIEN C R,et al.Favorable influence of age on tumor characteristics of sporadic colorectal adenocarcinoma:patients 30 year of age or younger may be a distinct patient group[J].Dis Colon Rectum,2003,46:904 -910.

共引文献29

同被引文献43

  • 1Saito T, Hama S, Izumi H. Centrosome amplification in- duced by surviving suppression enhances both chromosome instability and radiosensitivity in glioma cells [ J ]. Br J Cancer, 2008, 15 : 345 - 355.
  • 2王燕蓉,何仲义,刘娟.形态学实用技术.[M].上海:第二军大学出版社,2010,102-103.
  • 3Bavoux C, Hoffmann J S, Cazaux C. Adaptation to DNA damage and stimulation of genetic instability: the double- edged sword mammalian DNA polymerase kappa [ J ]. Bio- chimie, 2005,87:637 - 646.
  • 4Nojima K, Hochegger H, Saberi A, et al. Multiple repair pathways mediate tolerance to chemotherapeutic cross-link- ing agents in vertebrate ceils [ J ]. Cancer Res, 2005,65 : 11705 -11711.
  • 5Shen X,Jun S,O' Neal L,et al. REV3 and REV1 play major roles in recombination-independent repair of DNA inter- strand cross-links mediated by monoubiquitinated prolifera- ring cell nuclear antigen (PCNA) [ J ]. JBiol-Chem, 2006, 281 : 13869 - 13872.
  • 6Wu F, Lin X, Okuda T, et al. DNA polymeraseregulates cisplatin cytotoxicity, mutagenicity, and the rate of develop- ment of cisplatin resistance [ J ]. Cancer Res, 2004, 64 : 8029 - 8035.
  • 7Doles J, Oliver TG, Cameron ER et al. Suppression of REV3, the catalytic subunit of Pol { zeta } , sensitizes drug- resistant lung tumors to chemotherapy [ J ]. Proc Natl Acad Sci USA,2010.107:20786 - 20791.
  • 8黄金娟,隋御,李元杰等.REV3基因联合抗癌药物对SW-480细胞的影响[J].宁夏医科大学报,2012,34:561-564.
  • 9Andr6 T, Boni C, Navarro M, et al. hnproved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage 1] or lU colon cancer in the MOSAIC trial[J]. J Clin Oncol, 2009,27(19) :3109-3116.
  • 10Lin CC, Lin JK, Chang SC, et al. Is adjuvant chemotherapy benefi- cial to high risk stage H colon cancer? Analysis in a single institute [ J ]. Int J Colorectal Dis,2009,24 ( 6 ) :665-676.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部